Certara (NASDAQ:CERT) Price Target Raised to $13.00

Certara (NASDAQ:CERT) had its price target boosted by Barclays from $12.00 to $13.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price target points to a potential upside of 10.08% from the stock’s current price.

Other research analysts also recently issued research reports about the company. William Blair reiterated a “market perform” rating on shares of Certara in a report on Thursday. TD Cowen initiated coverage on shares of Certara in a research note on Thursday. They issued a “buy” rating and a $16.00 price objective for the company. Stephens restated an “overweight” rating and set a $17.00 price objective on shares of Certara in a research report on Thursday. Finally, Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Certara has an average rating of “Hold” and a consensus target price of $15.79.

Certara Stock Performance

Shares of CERT traded down $0.59 during trading hours on Friday, hitting $11.81. The company’s stock had a trading volume of 388,304 shares, compared to its average volume of 1,273,163. Certara has a 52-week low of $9.41 and a 52-week high of $19.87. The business has a 50 day simple moving average of $12.43 and a two-hundred day simple moving average of $11.64. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -59.08, a PEG ratio of 9.29 and a beta of 1.57.

Hedge Funds Weigh In On Certara

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Certara by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock valued at $132,455,000 after acquiring an additional 38,068 shares in the last quarter. Wasatch Advisors LP raised its stake in shares of Certara by 22.4% in the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock worth $105,577,000 after buying an additional 1,651,076 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its stake in shares of Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after buying an additional 3,861,674 shares in the last quarter. Geneva Capital Management LLC grew its holdings in shares of Certara by 0.7% in the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after acquiring an additional 37,392 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its holdings in shares of Certara by 13.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock valued at $48,542,000 after buying an additional 557,348 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.